How to audit a cell-therapy “success rate”
A percentage is uninterpretable without its denominator, outcome definition, time point, missing-data method, comparator, harms and source protocol.
Start with the denominator. Ask how many people began treatment, how many were eligible for analysis, how many reached the stated follow-up and why anyone was excluded. A percentage calculated only from patients who returned or supplied testimonials can overstate results. Outcomes should be reported for all assigned participants where the study design permits, with missing data described.
Define success before looking at the result. Pain score, walking distance, imaging, biomarker change, patient satisfaction, reduced medication and absence of disease progression are different outcomes. Ask which was primary, what change counted as clinically meaningful, when it was measured and whether the definition was set before data were examined. A statistically significant average change is not automatically a meaningful benefit for an individual.
Ask what happened without the intervention. Randomisation, an appropriate comparator, blinding and pre-specified analysis help separate treatment effects from natural variation, regression to the mean, concurrent care and expectation. An uncontrolled before-and-after series can describe what occurred but cannot by itself establish causation. Results from a different product, cell source, dose, route or indication do not validate the offered protocol.
Benefits and harms belong in the same table. Request all serious adverse events, treatment-emergent events, withdrawals, repeat procedures and rescue treatment, with follow-up long enough for plausible delayed risks. Ask whether the analysis was independent, whether the protocol and results are publicly accessible and whether the study was peer reviewed. Trial registration, ethics review and publication do not individually guarantee low bias or product approval.
The ISSCR patient guide distinguishes approved, investigational and unproven interventions, while EMA/HMA advise patients to verify the exact authorisation and evidence. If a clinic cannot supply a protocol-linked denominator and outcome definition, do not treat its headline percentage as decision-grade evidence.
Sources & further reading
- Stem-cell trials registry (ClinicalTrials.gov) ↗
- Peer-reviewed research (PubMed) ↗
- ISSCR — patient resources ↗
- FDA — consumer guidance ↗
- EMA — ATMP framework ↗
Commercial price observations are heterogeneous and most cell-therapy uses remain investigational. Verify source scope, regulatory status and the proposed care with an independent qualified physician.